Opendata, web and dolomites

BriScrew

BioResorbable Ostheosynthesis Implant

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BriScrew project word cloud

Explore the words cloud of the BriScrew project. It provides you a very rough idea of what is the project "BriScrew" about.

consists    screws    frequently    composition    qualified    materials    q3    employees    feeling    time    patient    bone    too    commercializing    investment    implants    alloyed    extremely    screw    surgery    total    off    biodegradable    hire    pain    remove    introduce    assurance    stiff    temperature    bri    bioresorbable    quality    implant    mg    medicine    orthopaedic    stimulates    secondary    alloy    reduces    sell    metal    injuries    treatment    81    gold    removal       revolutionary    zirconium    earn    titanium    risk    performed    healing    individuals    roi    risks    payback    osteosynthesis    conventional    global    generate    merely    shielding    organism    operation    foresee    steel    team    earth    ca    silver    zn    commercialization    adverse    almost    2020    pay    7m    standard    natural    2m    engineering    13    hospital    purified    unpredictable    minimize    healthcare    sales    market    surgical    fractures    stress    aluminium    900    magnesium    rare    profit    infections    launch    prevent    disease    95   

Project "BriScrew" data sheet

The following table provides information about the project.

Coordinator
BRI.TECH GMBH 

Organization address
address: ROSSMANNGASSE 21/4
city: GRAZ
postcode: 8010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website http://britech.eu/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRI.TECH GMBH AT (GRAZ) coordinator 50˙000.00

Map

 Project objective

In the EU, 20 % of all hospital treated injuries are bone fractures. If surgical treatment of bone fractures is necessary, it is currently performed with standard metal implants. Conventional gold-standard titanium or steel implants are too stiff, have adverse effects on the patient (feeling of pain during temperature changes) and lead to stress-shielding. Their usage is associated to the risk of infections and bone loss. Often a secondary surgery for removal is needed which is associated with almost 50 % higher healthcare costs. When Mg-based implants are used they are frequently alloyed with rare earth elements, aluminium, silver or zirconium. However, zirconium reduces the healing properties, aluminium and rare earth elements may remain in the organism and can lead to unpredictable effects, while the application of silver might result in a silver-disease.

Within the BRI.SCREW project we will introduce to the market revolutionary osteosynthesis implants that do not need surgical removal. We will use our own bioresorbable magnesium alloy which consists merely out of extremely high purified natural materials including Mg, Ca and Zn. BRI.SCREW is 100 % biodegradable, stimulates the healing process of the bone and has no side effects due to the implant's composition. Our orthopaedic implants will prevent the need of a second operation to remove the implant and will therefore minimize patient costs and surgical risks.

Our team consists of highly qualified individuals with experience in medicine, engineering and quality assurance. The investment in BRI.SCREW will pay off. We have estimated that after 5 years from launch, we will sell in total 81.900 BRI.SCREWs (sales €13.2M), hire 10 technical employees, and manage 5% of the global market. We will earn €8.7M profit and generate a ROI of 3.95 by commercializing this technology. We foresee the payback time in 2 years after commercialization (in Q3 of 2020).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRISCREW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRISCREW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More